Vaxcyte (PCVX) Accumulated Depreciation (2019 - 2023)

Vaxcyte (PCVX) has 5 years of Accumulated Depreciation data on file, last reported at $9.3 million in Q4 2023.

• On a quarterly basis, Accumulated Depreciation rose 51.58% year-over-year to $9.3 million in Q4 2023; TTM through Dec 2023 was $9.3 million, a 51.58% increase from a year earlier, with the FY2023 full-year figure at $9.3 million, up 51.58% from the prior year.
• Accumulated Depreciation for Q4 2023 stood at $9.3 million, up from $8.4 million in the prior quarter.
• Over the last five years, Accumulated Depreciation for PCVX reached as high as $9.3 million in Q4 2023 and fell as low as $3.0 million in Q4 2019.
• Historically, Accumulated Depreciation has averaged $5.3 million across 5 years, with a median of $4.8 million in 2021.
• Across the five-year window, Accumulated Depreciation retreated 13.4% in 2021 and jumped 72.41% in 2022, its largest moves.
• Year by year, Accumulated Depreciation stood at $3.0 million in 2019, then jumped by 37.39% to $4.1 million in 2020, then declined by 13.4% to $3.5 million in 2021, then surged by 72.41% to $6.1 million in 2022, then surged by 51.58% to $9.3 million in 2023.
• Per Business Quant data, the three most recent Accumulated Depreciation figures were $9.3 million in Q4 2023, $8.4 million in Q3 2023, and $7.6 million in Q2 2023.